UCB.BR - UCB SA

Brussels - Brussels Delayed Price. Currency in EUR
70.36
+0.80 (+1.15%)
As of 11:01AM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close69.56
Open69.58
Bid0.00 x 0
Ask0.00 x 0
Day's Range69.54 - 70.50
52 Week Range65.42 - 81.48
Volume31,404
Avg. Volume307,219
Market Cap13.292B
Beta (3Y Monthly)0.53
PE Ratio (TTM)16.59
EPS (TTM)4.24
Earnings DateJul 25, 2019
Forward Dividend & Yield1.21 (1.77%)
Ex-Dividend Date2019-04-29
1y Target Est74.54
  • PR Newswire4 days ago

    UCB's Key Pipeline Molecule Bimekizumab Demonstrated Improved Outcomes for Ankylosing Spondylitis Patients

    -- New Phase 2b bimekizumab data showed the novel investigational molecule delivered improvements in disease activity and in important patient-reported outcomes, such as pain, fatigue, morning stiffness, ...

  • What Do Analysts Think About The Future Of UCB SA's (EBR:UCB)?
    Simply Wall St.18 days ago

    What Do Analysts Think About The Future Of UCB SA's (EBR:UCB)?

    In December 2018, UCB SA (EBR:UCB) released its earnings update. Generally, the consensus outlook from analysts appear...

  • UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.
    PR Newswire29 days ago

    UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.

    - NAYZILAM® (midazolam) nasal spray CIV is a nasally administered benzodiazepine indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, ...

  • A Look At The Intrinsic Value Of UCB SA (EBR:UCB)
    Simply Wall St.last month

    A Look At The Intrinsic Value Of UCB SA (EBR:UCB)

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • UCB SA (EBR:UCB): Ex-Dividend Is In 3 Days
    Simply Wall St.2 months ago

    UCB SA (EBR:UCB): Ex-Dividend Is In 3 Days

    If you are interested in cashing in on UCB SA's (EBR:UCB) upcoming dividend of €0.85 per share, you only have 3 days left to buy the shares before its ex-dividend date, 26 April 2019, in time for dividends payable on the 30 April 2019...

  • Reuters2 months ago

    Amgen's postmenopausal osteoporosis drug gets FDA greenlight

    The U.S. Food and Drug Administration said on Tuesday it had approved Amgen Inc's osteoporosis treatment for postmenopausal women who are at high risk of fracture. Postmenopausal osteoporosis is a chronic condition resulting from progressive bone loss beginning around menopause. The monthly injection, Evenity, developed jointly with Belgium-based UCB SA, helps reduce the risk of fracture by increasing bone mass and mildly inhibiting the break down of bone minerals.

  • PR Newswire2 months ago

    FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

    THOUSAND OAKS, Calif. and BRUSSELS, April 9, 2019 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has approved EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY is the first and only bone builder with a unique dual effect that both increases bone formation and to a lesser extent reduces bone resorption (or bone loss) to rapidly reduce the risk of fracture.

  • A Note On UCB SA's (EBR:UCB) ROE and Debt To Equity
    Simply Wall St.3 months ago

    A Note On UCB SA's (EBR:UCB) ROE and Debt To Equity

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for th...

  • PR Newswire3 months ago

    CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis

    FDA approval was based on the C-AXSPAND Phase 3 study in adults with non-radiographic axial spondyloarthritis, which demonstrated rapid and major improvement response with CIMZIA compared to placebo. BRUSSELS, March 28, 2019 /PRNewswire/ -- UCB, a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved extending the label for CIMZIA® (certolizumab pegol) to include a new indication for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. The approval makes CIMZIA the first and only FDA-approved  treatment for nr-axSpA.

  • UCB SA (EBR:UCB): What’s The Analyst Consensus Outlook?
    Simply Wall St.3 months ago

    UCB SA (EBR:UCB): What’s The Analyst Consensus Outlook?

    In December 2018, UCB SA (EBR:UCB) announced its most recent earnings update, which revealed that the company benefited from a small tailwind, leading to a single-digit earnings growth of 5.3%.Read More...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of UCB.BR earnings conference call or presentation 28-Feb-19 1:00pm GMT

    Q4 2018 Ucb SA Earnings Call

  • PR Newswire3 months ago

    Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study

    - 80 to 100% of BE ABLE 1 responders maintained a response of at least 90% disease improvement (PASI90) over 60 weeks with bimekizumab - These positive results mark the longest-term data to date demonstrating ...

  • PR Newswire4 months ago

    New Data Affirms Strength of UCB Immuno-Dermatology Portfolio

    - Late breaking presentation of the Phase 2b long-term findings on the investigational molecule, bimekizumab, demonstrates complete or almost complete skin clearance in moderate-to-severe plaque psoriasis ...

  • What Kind Of Shareholders Own UCB SA (EBR:UCB)?
    Simply Wall St.4 months ago

    What Kind Of Shareholders Own UCB SA (EBR:UCB)?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! The big shareholder groups in UCB SA (EBR:UCB) have powerRead More...

  • Should UCB SA (EBR:UCB) Be Part Of Your Dividend Portfolio?
    Simply Wall St.5 months ago

    Should UCB SA (EBR:UCB) Be Part Of Your Dividend Portfolio?

    A sizeable part of portfolio returns can be produced by dividend stocks due to their contribution to compounding returns in the long run. Historically, UCB SA (EBR:UCB) has paid a Read More...

  • Reuters5 months ago

    Amgen's postmenopausal osteoporosis drug wins FDA panel backing

    An advisory panel to the U.S. Food and Drug Administration said on Wednesday that benefits of Amgen Inc's osteoporosis treatment for postmenopausal women at high risk for fracture outweighed its risks and overwhelmingly voted for the drug's approval. The panel voted 16-1 in favor of the monthly injection developed jointly with Belgium-based UCB SA. The drug, Evenity, helps reduce the risk of fracture by increasing bone formation and inhibiting break down of bone minerals. The panel, however, raised concerns of cardiovascular safety risks linked to the drug, which FDA staff reviewers on Monday had cited as the main reason for convening the panel meeting.

  • PR Newswire5 months ago

    Amgen And UCB Receive Positive Vote From FDA Advisory Committee In Favor Of Approval For EVENITY™ (romosozumab)

    THOUSAND OAKS, Calif. and BRUSSELS, Jan. 16, 2019 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced strong support from the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the approval of EVENITY™* (romosozumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture after reviewing safety and efficacy data from the pivotal Phase 3 studies. "We are pleased with the Committee's recommendation to approve EVENITY for the treatment of postmenopausal women with osteoporosis at high risk for fracture," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.

  • PR Newswire5 months ago

    EVENITY™ (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture

    THOUSAND OAKS, Calif. and BRUSSELS, Belgium, Jan. 8, 2019 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that the Japanese Ministry of Health, Labor and Welfare has granted a marketing authorization for EVENITY™ (romosozumab) for the treatment of osteoporosis in patients at high risk of fracture.1 Amgen and UCB are co-developing EVENITY worldwide, with development in Japan being led by Amgen Astellas BioPharma K.K., a joint venture between Amgen and Astellas Pharma Inc., headquartered in Tokyo.

  • Simply Wall St.6 months ago

    An Examination Of UCB SA (EBR:UCB)

    As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I look at stocks holistically, from their financial health to Read More...

  • Reuters6 months ago

    Drugmaker UCB backs Brexit Britain with 1 billion pound investment

    Belgian drugmaker UCB (UCB.BR) expects to invest about 1 billion pounds in Britain over the next five years, throwing its support behind the country's life sciences sector despite Brexit uncertainty. The move is a fillip for Prime Minister Theresa May, who is battling to win support for a Dec. 11 parliamentary vote on her agreement with Brussels on Britain leaving the European Union next March. UCB said on Wednesday that its investment would include 150 million to 200 million pounds on a purpose-built research centre.

  • PR Newswire7 months ago

    Amgen And UCB Announce FDA Advisory Committee Meeting To Review EVENITY™ (romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

    THOUSAND OAKS, Calif. and BRUSSELS, Nov. 30, 2018 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) will review data supporting the Biologics License Application (BLA) for EVENITYTM (romosozumab) for the treatment of osteoporosis in postmenopausal women at high risk for fracture at a meeting on Jan. 16, 2019. "After a fracture, postmenopausal women with osteoporosis are five times more likely to fracture in the subsequent year, and these fractures can be life-changing.